Matinas BioPharma (MTNB) Stock Price Down 7.4%

Shares of Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) were down 7.4% during trading on Friday . The company traded as low as $1.10 and last traded at $1.13. Approximately 1,580,112 shares changed hands during mid-day trading, an increase of 30% from the average daily volume of 1,219,598 shares. The stock had previously closed at $1.22.

Separately, Roth Capital initiated coverage on Matinas BioPharma in a research report on Monday, February 11th. They set a “buy” rating and a $4.75 target price on the stock.

Institutional investors have recently made changes to their positions in the company. Private Advisor Group LLC raised its position in Matinas BioPharma by 100.4% during the fourth quarter. Private Advisor Group LLC now owns 49,850 shares of the company’s stock valued at $30,000 after buying an additional 24,978 shares during the period. Northern Trust Corp raised its position in Matinas BioPharma by 18.9% during the fourth quarter. Northern Trust Corp now owns 182,641 shares of the company’s stock valued at $109,000 after buying an additional 29,072 shares during the period. D. E. Shaw & Co. Inc. acquired a new position in Matinas BioPharma during the fourth quarter valued at $26,000. Virtu Financial LLC acquired a new position in Matinas BioPharma during the fourth quarter valued at $39,000. Finally, Renaissance Technologies LLC raised its position in Matinas BioPharma by 325.6% during the third quarter. Renaissance Technologies LLC now owns 134,900 shares of the company’s stock valued at $124,000 after buying an additional 103,200 shares during the period.

TRADEMARK VIOLATION NOTICE: This story was first reported by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://dakotafinancialnews.com/2019/03/24/matinas-biopharma-mtnb-stock-price-down-7-4.html.



Matinas BioPharma Company Profile (NYSEAMERICAN:MTNB)

Matinas BioPharma Holdings, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. The company enables the delivery of life-changing medicines using its lipid nano-crystal (LNC) platform technology. Its LNC delivery technology platform utilizes lipid nano-crystals which can encapsulate small molecules, oligonucleotides, vaccines, peptides, proteins and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable.

Recommended Story: Institutional Investors

Receive News & Ratings for Matinas BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.